182 related articles for article (PubMed ID: 38539538)
21. Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?
Rooper LM; Gagan J; Bishop JA
Head Neck Pathol; 2022 Dec; 16(4):1063-1072. PubMed ID: 35794510
[TBL] [Abstract][Full Text] [Related]
22. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
23. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
24. Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.
Can NT; Lingen MW; Mashek H; McElherne J; Briese R; Fitzpatrick C; van Zante A; Cipriani NA
Head Neck Pathol; 2018 Mar; 12(1):95-104. PubMed ID: 28681314
[TBL] [Abstract][Full Text] [Related]
25. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.
Jalaly JB; Sanati S; Chernock RD; Dibe DG; El-Mofty SK
Head Neck Pathol; 2018 Dec; 12(4):488-492. PubMed ID: 29302899
[TBL] [Abstract][Full Text] [Related]
26. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
Yang RK; Zhao P; Lu C; Luo J; Hu R
Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
[TBL] [Abstract][Full Text] [Related]
27. Salivary duct carcinoma of the parotid gland: A case report and review of the literature.
Xie S; Yang H; Bredell M; Shen S; Yang H; Jin L; Zhang S
Oncol Lett; 2015 Jan; 9(1):371-374. PubMed ID: 25435994
[TBL] [Abstract][Full Text] [Related]
28. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
29. Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade.
Lassche G; Tada Y; van Herpen CML; Jonker MA; Nagao T; Saotome T; Hirai H; Saigusa N; Takahashi H; Ojiri H; van Engen-Van Grunsven ACH; Schalken JA; Fushimi C; Verhaegh GW
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298742
[TBL] [Abstract][Full Text] [Related]
30. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
31. Salivary Duct Carcinoma with Rhabdoid Features of the Parotid Gland with No E-Cadherin Expression: A Report with Anti-HER2 Therapy and Review of the Literature.
Jain R; Sansoni ER; Angel J; Gleysteen JP; Hayes DN; Owosho AA
Dent J (Basel); 2023 Sep; 11(10):. PubMed ID: 37886914
[TBL] [Abstract][Full Text] [Related]
32. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
33. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
[TBL] [Abstract][Full Text] [Related]
34. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
[TBL] [Abstract][Full Text] [Related]
35. Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Rieke DT; Schröder S; Schafhausen P; Blanc E; Zuljan E; von der Emde B; Beule D; Keller U; Keilholz U; Klinghammer K
Front Oncol; 2023; 13():1107134. PubMed ID: 37427101
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
37. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
38. First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.
Viscuse PV; Price KA; Garcia JJ; Schembri-Wismayer DJ; Chintakuntlawar AV
Front Oncol; 2019; 9():701. PubMed ID: 31428578
[No Abstract] [Full Text] [Related]
39. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
[TBL] [Abstract][Full Text] [Related]
40. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
Liang L; Williams MD; Bell D
Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
